Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05363280 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

StatusRecruiting
PhasePhase 2
Started2022-11-01
View on ClinicalTrials.gov ↗
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .

Amendment record

Amended 9 times since 2022-05-02; most recent filed 2026-05-05. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-05-05
Amendment Active, Not Recruiting→Recruiting Study Identification, Study Status, Oversight, Study Description, Conditions, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v9
2025-09-18
Amendment Recruiting→Active, Not Recruiting Study Status, Oversight, Contacts/Locations v8
2024-07-12
Amendment Study Status, Contacts/Locations v7
2024-03-08
Amendment Study Status, Contacts/Locations v6
2023-12-04
Amendment Study Identification, Study Status, Contacts/Locations v5
2023-10-19
Amendment Study Status, Contacts/Locations v4
2023-10-02
Amendment Study Status, Contacts/Locations v3
2022-11-01
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
2022-10-20
Amendment Study Status v1
2022-05-02
Original filing
Trial Details
NCT Number NCT05363280
Lead Sponsor Advenchen Pharmaceuticals, LLC.
Conditions Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
Enrollment 80 participants
Start Date 2022-11-01
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-08